Targeting the β-catenin nuclear transport pathway in cancer

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 20-29

  Jamieson, Cara ^a   Sharma, Manisha ^a   Henderson, Beric R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Nuclear envelope; Nuclear transport; Wnt signaling; Catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CWP 232291; KARYOPHERIN; LGK 974; LYMPHOID ENHANCER FACTOR 1; NUCLEOPORIN; OMP 18R 5; OMP 54F 28; PRI 724; RAN PROTEIN; SELINEXOR; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPLEX FORMATION; DRUG TARGETING; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR IMPORT; NUCLEAR PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSACTIVATION; ACTIVE TRANSPORT; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; WNT SIGNALING PATHWAY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BETA CATENIN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84904471182     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.04.012     Document Type: Review

References (153)

1. Nigg E.A. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 1997, 386:779-787.
2. Gorlich D. Transport into and out of the cell nucleus. EMBO J 1998, 17:2721-2727.
3. Gorlich D., Dabrowski M., Bischoff F.R., Kutay U., Bork P., Hartmann E., et al. A novel class of RanGTP binding proteins. J Cell Biol 1997, 138:65-80.
4. Terry L.J., Wente S.R. Nuclear mRNA export requires specific FG nucleoporins for translocation through the nuclear pore complex. J Cell Biol 2007, 178:1121-1132.
5. Fabbro M., Henderson B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003, 282:59-69.
6. Kau T.R., Way J.C., Silver P.A. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004, 4:106-117.
7. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
8. Nguyen K.T., Holloway M.P., Altura R.A. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012, 3:137-151.
9. Henderson B.R. Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. Bioessays 2005, 27:884-893.
10. Brocardo M., Henderson B.R. APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol 2008, 18:587-596.
11. Chahine M.N., Pierce G.N. Therapeutic targeting of nuclear protein import in pathological cell conditions. Pharmacol Rev 2009, 61:358-372.
12. Ptak C., Aitchison J.D., Wozniak R.W. The multifunctional nuclear pore complex: a platform for controlling gene expression. Curr Opin Cell Biol 2014, 28C:46-53.
13. Hoelz A., Debler E.W., Blobel G. The structure of the nuclear pore complex. Annu Rev Biochem 2011, 80:613-643.
14. Adams R.L., Wente S.R. Uncovering nuclear pore complexity with innovation. Cell 2013, 152:1218-1221.
15. D'Angelo M.A., Hetzer M.W. Structure, dynamics and function of nuclear pore complexes. Trends Cell Biol 2008, 18:456-466.
16. Stewart M. Molecular mechanism of the nuclear protein import cycle. Nat Rev Mol Cell Biol 2007, 8:195-208.
17. Bayliss R., Corbett A.H., Stewart M. The molecular mechanism of transport of macromolecules through nuclear pore complexes. Traffic 2000, 1:448-456.
18. Walde S., Kehlenbach R.H. The part and the whole: functions of nucleoporins in nucleocytoplasmic transport. Trends Cell Biol 2010, 20:461-469.
19. Fried H., Kutay U. Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 2003, 60:1659-1688.
20. Cook A.G., Conti E. Nuclear export complexes in the frame. Curr Opin Struct Biol 2010, 20:247-252.
21. Jamali T., Jamali Y., Mehrbod M., Mofrad M.R. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev Cell Mol Biol 2011, 287:233-286.
22. Terry L.J., Wente S.R. Flexible gates: dynamic topologies and functions for FG nucleoporins in nucleocytoplasmic transport. Eukaryot Cell 2009, 8:1814-1827.
23. Xu L., Alarcon C., Col S., Massague J. Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. J Biol Chem 2003, 278:42569-42577.
24. Matsubayashi Y., Fukuda M., Nishida E. Evidence for existence of a nuclear pore complex-mediated, cytosol-independent pathway of nuclear translocation of ERK MAP kinase in permeabilized cells. J Biol Chem 2001, 276:41755-41760.
25. Whitehurst A.W., Wilsbacher J.L., You Y., Luby-Phelps K., Moore M.S., Cobb M.H. ERK2 enters the nucleus by a carrier-independent mechanism. Proc Natl Acad Sci U S A 2002, 99:7496-7501.
26. Marg A., Shan Y., Meyer T., Meissner T., Brandenburg M., Vinkemeier U. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 2004, 165:823-833.
27. Takahashi N., van Kilsdonk J.W., Ostendorf B., Smeets R., Bruggeman S.W., Alonso A., et al. Tumor marker nucleoporin 88kDa regulates nucleocytoplasmic transport of NF-kappaB. Biochem Biophys Res Commun 2008, 374:424-430.
28. Kumar S., Chaturvedi N.K., Nishi M., Kawata M., Tyagi R.K. Shuttling components of nuclear import machinery involved in nuclear translocation of steroid receptors exit nucleus via exportin-1/CRM-1* independent pathway. Biochim Biophys Acta 2004, 1691:73-77.
29. Lischka P., Rosorius O., Trommer E., Stamminger T. A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J 2001, 20:7271-7283.
30. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
31. Tanaka S.S., Kojima Y., Yamaguchi Y.L., Nishinakamura R., Tam P.P. Impact of WNT signaling on tissue lineage differentiation in the early mouse embryo. Dev Growth Differ 2011, 53:843-856.
32. Valenta T., Hausmann G., Basler K. The many faces and functions of beta-catenin. EMBO J 2012, 31:2714-2736.
33. Kim W., Kim M., Jho E.H. Wnt/beta-catenin signalling: from plasma membrane to nucleus. Biochem J 2013, 450:9-21.
34. Henderson B.R., Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 2002, 3:834-839.
35. Jamieson C., Sharma M., Henderson B.R. Wnt signaling from membrane to nucleus: beta-catenin caught in a loop. Int J Biochem Cell Biol 2012, 44:847-850.
36. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98:10356-10361.
37. Kirchner T., Brabletz T. Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol 2000, 157:1113-1121.
38. Huber A.H., Nelson W.J., Weis W.I. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 1997, 90:871-882.
39. Solanas G., Miravet S., Casagolda D., Castano J., Raurell I., Corrionero A., et al. beta-Catenin and plakoglobin N- and C-tails determine ligand specificity. J Biol Chem 2004, 279:49849-49856.
40. Choi H.J., Huber A.H., Weis W.I. Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem 2006, 281:1027-1038.
41. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
42. Fagotto F., Gluck U., Gumbiner B.M. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 1998, 8:181-190.
43. Yokoya F., Imamoto N., Tachibana T., Yoneda Y. beta-catenin can be transported into the nucleus in a Ran-unassisted manner. Mol Biol Cell 1999, 10:1119-1131.
44. Eleftheriou A., Yoshida M., Henderson B.R. Nuclear export of human beta-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor. J Biol Chem 2001, 276:25883-25888.
45. Wiechens N., Fagotto F. CRM1- and Ran-independent nuclear export of beta-catenin. Curr Biol 2001, 11:18-27.
46. Sharma M., Jamieson C., Johnson M., Molloy M.P., Henderson B.R. Specific armadillo repeat sequences facilitate beta-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153 and RANBP2/Nup358. J Biol Chem 2012, 287:819-831.
47. Johnson M., Sharma M., Jamieson C., Henderson J.M., Mok M.T., Bendall L., et al. Regulation of beta-catenin trafficking to the membrane in living cells. Cell Signal 2009, 21:339-348.
48. Krieghoff E., Behrens J., Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci 2006, 119:1453-1463.
49. Jamieson C., Sharma M., Henderson B.R. Regulation of beta-catenin nuclear dynamics by GSK-3beta involves a LEF-1 positive feedback loop. Traffic 2011, 12:983-999.
50. Lee S.J., Imamoto N., Sakai H., Nakagawa A., Kose S., Koike M., et al. The adoption of a twisted structure of importin-beta is essential for the protein-protein interaction required for nuclear transport. J Mol Biol 2000, 302:251-264.
51. Conti E., Muller C.W., Stewart M. Karyopherin flexibility in nucleocytoplasmic transport. Curr Opin Struct Biol 2006, 16:237-244.
52. Suh E.K., Gumbiner B.M. Translocation of beta-catenin into the nucleus independent of interactions with FG-rich nucleoporins. Exp Cell Res 2003, 290:447-456.
53. Walde S., Thakar K., Hutten S., Spillner C., Nath A., Rothbauer U., et al. The nucleoporin Nup358/RanBP2 promotes nuclear import in a cargo- and transport receptor-specific manner. Traffic 2012, 13:218-233.
54. Hamada M., Haeger A., Jeganathan K.B., van Ree J.H., Malureanu L., Walde S., et al. Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability. J Cell Biol 2011, 194:597-612.
55. Funasaka T., Wong R.W. The role of nuclear pore complex in tumor microenvironment and metastasis. Cancer Metastasis Rev 2011, 30:239-251.
56. Kalverda B., Pickersgill H., Shloma V.V., Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010, 140:360-371.
57. Capelson M., Liang Y., Schulte R., Mair W., Wagner U., Hetzer M.W. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 2010, 140:372-383.
58. Vaquerizas J.M., Suyama R., Kind J., Miura K., Luscombe N.M., Akhtar A. Nuclear pore proteins nup153 and megator define transcriptionally active regions in the Drosophila genome. PLoS Genet 2010, 6:e1000846.
59. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
60. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
61. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
62. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
63. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B., et al. Identification of FAP locus genes from chromosome 5q21. Science 1991, 253:661-665.
64. Wong S.C., Lo E.S., Lee K.C., Chan J.K., Hsiao W.L. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004, 10:1401-1408.
65. Stanczak A., Stec R., Bodnar L., Olszewski W., Cichowicz M., Kozlowski W., et al. Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res 2011, 17:955-963.
66. Kobayashi M., Honma T., Matsuda Y., Suzuki Y., Narisawa R., Ajioka Y., et al. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 2000, 82:1689-1693.
67. Khiari M., Arfaoui A., Kriaa L., Chaar I., Amara S., Lounis M.A., et al. The prognostic value of the immunohistochemical expression and mutational pattern of the key mediator of Wnt signaling: beta-catenin in Tunisian patients with colorectal carcinoma. Appl Immunohistochem Mol Morphol 2012, 20:62-70.
68. Bustos V.H., Ferrarese A., Venerando A., Marin O., Allende J.E., Pinna L.A. The first armadillo repeat is involved in the recognition and regulation of beta-catenin phosphorylation by protein kinase CK1. Proc Natl Acad Sci U S A 2006, 103:19725-19730.
69. Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N., Garcia de Herreros A., et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 2003, 23:2287-2297.
70. Brembeck F.H., Rosario M., Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006, 16:51-59.
71. Piedra J., Martinez D., Castano J., Miravet S., Dunach M., de Herreros A.G. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 2001, 276:20436-20443.
72. Huber A.H., Weis W.I. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001, 105:391-402.
73. Coluccia A.M., Benati D., Dekhil H., De Filippo A., Lan C., Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006, 66:2279-2286.
74. Wu X., Tu X., Joeng K.S., Hilton M.J., Williams D.A., Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 2008, 133:340-353.
75. Cong F., Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A 2004, 101:2882-2887.
76. Li F.Q., Mofunanya A., Harris K., Takemaru K. Chibby cooperates with 14-3-3 to regulate beta-catenin subcellular distribution and signaling activity. J Cell Biol 2008, 181:1141-1154.
77. Cao Y., Liu R., Jiang X., Lu J., Jiang J., Zhang C., et al. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. Mol Cell Biol 2009, 29:5477-5487.
78. Li Y., Shao Y., Tong Y., Shen T., Zhang J., Gu H., et al. Nucleo-cytoplasmic shuttling of PAK4 modulates beta-catenin intracellular translocation and signaling. Biochim Biophys Acta 2012, 1823:465-475.
79. Wang Y., Kakinuma N., Zhu Y., Kiyama R. Nucleo-cytoplasmic shuttling of human Kank protein accompanies intracellular translocation of beta-catenin. J Cell Sci 2006, 119:4002-4010.
80. Thyssen G., Li T.H., Lehmann L., Zhuo M., Sharma M., Sun Z. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol Cell Biol 2006, 26:8857-8867.
81. Jian H., Shen X., Liu I., Semenov M., He X., Wang X.F. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev 2006, 20:666-674.
82. Zhang N., Wei P., Gong A., Chiu W.T., Lee H.T., Colman H., et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20:427-442.
83. Chen J., Wu A., Sun H., Drakas R., Garofalo C., Cascio S., et al. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin. J Biol Chem 2005, 280:29912-29920.
84. Wen Y., Caffrey T.C., Wheelock M.J., Johnson K.R., Hollingsworth M.A. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 2003, 278:38029-38039.
85. Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S., Hammerschmidt M., Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev 2004, 18:2225-2230.
86. Mulholland D.J., Cheng H., Reid K., Rennie P.S., Nelson C.C. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002, 277:17933-17943.
87. Asally M., Yoneda Y. Beta-catenin can act as a nuclear import receptor for its partner transcription factor, lymphocyte enhancer factor-1 (lef-1). Exp Cell Res 2005, 308:357-363.
88. Hsu H.T., Liu P.C., Ku S.Y., Jung K.C., Hong Y.R., Kao C., et al. Beta-catenin control of T-cell transcription factor 4 (Tcf4) importation from the cytoplasm to the nucleus contributes to Tcf4-mediated transcription in 293 cells. Biochem Biophys Res Commun 2006, 343:893-898.
89. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
90. Henderson B.R., Galea M., Schuechner S., Leung L. Lymphoid enhancer factor-1 blocks adenomatous polyposis coli-mediated nuclear export and degradation of beta-catenin. Regulation by histone deacetylase 1. J Biol Chem 2002, 277:24258-24264.
91. Kramps T., Peter O., Brunner E., Nellen D., Froesch B., Chatterjee S., et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002, 109:47-60.
92. Townsley F.M., Cliffe A., Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 2004, 6:626-633.
93. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86:391-399.
94. Hovanes K., Li T.W., Munguia J.E., Truong T., Milovanovic T., Lawrence Marsh J., et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001, 28:53-57.
95. de la Roche M., Ibrahim A.E., Mieszczanek J., Bienz M. LEF1 and B9L shield beta-catenin from inactivation by axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 2014, 74:1495-1505.
96. Li T.W., Ting J.H., Yokoyama N.N., Bernstein A., van de Wetering M., Waterman M.L. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol 2006, 26:5284-5299.
97. Knapp S., Zamai M., Volpi D., Nardese V., Avanzi N., Breton J., et al. Thermodynamics of the high-affinity interaction of TCF4 with beta-catenin. J Mol Biol 2001, 306:1179-1189.
98. Kengaku M., Capdevila J., Rodriguez-Esteban C., De La Pena J., Johnson R.L., Izpisua Belmonte J.C., et al. Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud. Science 1998, 280:1274-1277.
99. Atcha F.A., Munguia J.E., Li T.W., Hovanes K., Waterman M.L. A new beta-catenin-dependent activation domain in T cell factor. J Biol Chem 2003, 278:16169-16175.
100. Filali M., Cheng N., Abbott D., Leontiev V., Engelhardt J.F. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 2002, 277:33398-33410.
101. Amen M., Liu X., Vadlamudi U., Elizondo G., Diamond E., Engelhardt J.F., et al. PITX2 and beta-catenin interactions regulate Lef-1 isoform expression. Mol Cell Biol 2007, 27:7560-7573.
102. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.W., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100-107.
103. Gong Y., Bourhis E., Chiu C., Stawicki S., DeAlmeida V.I., Liu B.Y., et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010, 5:e12682.
104. Ettenberg S.A., Charlat O., Daley M.P., Liu S., Vincent K.J., Stuart D.D., et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci U S A 2010, 107:15473-15478.
105. Gurney A., Axelrod F., Bond C.J., Cain J., Chartier C., Donigan L., et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 2012, 109:11717-11722.
106. Shan J., Shi D.L., Wang J., Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44:15495-15503.
107. Grandy D., Shan J., Zhang X., Rao S., Akunuru S., Li H., et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009, 284:16256-16263.
108. Fujii N., You L., Xu Z., Uematsu K., Shan J., He B., et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007, 67:573-579.
109. Thorne C.A., Hanson A.J., Schneider J., Tahinci E., Orton D., Cselenyi C.S., et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010, 6:829-836.
110. Waaler J., Machon O., von Kries J.P., Wilson S.R., Lundenes E., Wedlich D., et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 2011, 71:197-205.
111. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
112. Hua Z., Bregman H., Buchanan J.L., Chakka N., Guzman-Perez A., Gunaydin H., et al. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem 2013, 56:10003-10015.
113. Lau T., Chan E., Callow M., Waaler J., Boggs J., Blake R.A., et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 2013, 73:3132-3144.
114. Qian L., Mahaffey J.P., Alcorn H.L., Anderson K.V. Tissue-specific roles of Axin2 in the inhibition and activation of Wnt signaling in the mouse embryo. Proc Natl Acad Sci U S A 2011, 108:8692-8697.
115. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:552-566.
116. Takahashi-Yanaga F., Taba Y., Miwa Y., Kubohara Y., Watanabe Y., Hirata M., et al. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem 2003, 278:9663-9670.
117. Yasmin T., Takahashi-Yanaga F., Mori J., Miwa Y., Hirata M., Watanabe Y., et al. Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells. Biochem Biophys Res Commun 2005, 338:903-909.
118. Snow C.M., Senior A., Gerace L. Monoclonal antibodies identify a group of nuclear pore complex glycoproteins. J Cell Biol 1987, 104:1143-1156.
119. Gasiorowski J.Z., Dean D.A. Mechanisms of nuclear transport and interventions. Adv Drug Deliv Rev 2003, 55:703-716.
120. Finlay D.R., Newmeyer D.D., Price T.M., Forbes D.J. Inhibition of in vitro nuclear transport by a lectin that binds to nuclear pores. J Cell Biol 1987, 104:189-200.
121. Takeda A., Yaseen N.R. Nucleoporins and nucleocytoplasmic transport in hematologic malignancies. Semin Cancer Biol 2014, 27:3-10.
122. Kosugi S., Hasebe M., Entani T., Takayama S., Tomita M., Yanagawa H. Design of peptide inhibitors for the importin alpha/beta nuclear import pathway by activity-based profiling. Chem Biol 2008, 15:940-949.
123. Ambrus G., Whitby L.R., Singer E.L., Trott O., Choi E., Olson A.J., et al. Small molecule peptidomimetic inhibitors of importin alpha/beta mediated nuclear transport. Bioorg Med Chem 2010, 18:7611-7620.
124. Hintersteiner M., Ambrus G., Bednenko J., Schmied M., Knox A.J., Meisner N.C., et al. Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. ACS Chem Biol 2010, 5:967-979.
125. Soderholm J.F., Bird S.L., Kalab P., Sampathkumar Y., Hasegawa K., Uehara-Bingen M., et al. Importazole, a small molecule inhibitor of the transport receptor importin-beta. ACS Chem Biol 2011, 6:700-708.
126. Graham T.A., Clements W.K., Kimelman D., Xu W. The crystal structure of the beta-catenin/ICAT complex reveals the inhibitory mechanism of ICAT. Mol Cell 2002, 10:563-571.
127. Sakamoto I., Kishida S., Fukui A., Kishida M., Yamamoto H., Hino S., et al. A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J Biol Chem 2000, 275:32871-32878.
128. Weiske J., Albring K.F., Huber O. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc Natl Acad Sci U S A 2007, 104:20344-20349.
129. Ghogomu S.M., van Venrooy S., Ritthaler M., Wedlich D., Gradl D. HIC-5 is a novel repressor of lymphoid enhancer factor/T-cell factor-driven transcription. J Biol Chem 2006, 281:1755-1764.
130. Kanamori M., Sandy P., Marzinotto S., Benetti R., Kai C., Hayashizaki Y., et al. The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem 2003, 278:38758-38764.
131. Eklof Spink K., Fridman S.G., Weis W.I. Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J 2001, 20:6203-6212.
132. Xing Y., Clements W.K., Kimelman D., Xu W. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. Genes Dev 2003, 17:2753-2764.
133. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5:91-102.
134. Hermiston M.L., Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995, 270:1203-1207.
135. von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T., Sochnikova N., Dell'Oro A., et al. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 2000, 7:800-807.
136. Wang W., Liu H., Wang S., Hao X., Li L. A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/beta-catenin signaling and colon cancer cell tumorigenesis. Cell Res 2011, 21:730-740.
137. Gonsalves F.C., Klein K., Carson B.B., Katz S., Ekas L.A., Evans S., et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A 2011, 108:5954-5963.
138. Dehnhardt C.M., Venkatesan A.M., Chen Z., Ayral-Kaloustian S., Dos Santos O., Delos Santos E., et al. Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem 2010, 53:897-910.
139. Lee S.H., Richardson R.L., Dashwood R.H., Baek S.J. Capsaicin represses transcriptional activity of beta-catenin in human colorectal cancer cells. J Nutr Biochem 2011, 23:646-655.
140. Park S., Chun S. Streptonigrin inhibits beta-Catenin/Tcf signaling and shows cytotoxicity in beta-catenin-activated cells. Biochim Biophys Acta 2010, 1810:1340-1345.
141. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005, 19:1353-1355.
142. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 2007, 73:1318-1329.
143. Takahashi-Yanaga F., Yoshihara T., Jingushi K., Miwa Y., Morimoto S., Hirata M., et al. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochem Biophys Res Commun 2008, 377:1185-1190.
144. Eguchi M., Nguyen C., Lee S.C., Kahn M. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem 2005, 1:467-472.
145. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004, 101:12682-12687.
146. Takada K., Zhu D., Bird G.H., Sukhdeo K., Zhao J.J., Mani M., et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 2012, 4:148ra117.
147. Kawamoto S.A., Coleska A., Ran X., Yi H., Yang C.Y., Wang S. Design of triazole-stapled BCL9 alpha-helical peptides to target the beta-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J Med Chem 2012, 55:1137-1146.
148. de la Roche M., Rutherford T.J., Gupta D., Veprintsev D.B., Saxty B., Freund S.M., et al. An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. Nat Commun 2012, 3:680.
149. Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012, 31:2737-2746.
150. Ewan K., Pajak B., Stubbs M., Todd H., Barbeau O., Quevedo C., et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res 2010, 70:5963-5973.
151. Garber K. Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 2009, 101:548-550.
152. Park S., Gwak J., Cho M., Song T., Won J., Kim D.E., et al. Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 2006, 70:960-966.
153. Gwak J., Song T., Song J.Y., Yun Y.S., Choi I.W., Jeong Y., et al. Isoreserpine promotes beta-catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells. Biochem Biophys Res Commun 2009, 387:444-449.